Year: 2025

Joint Development Agreement will establish a foundation for ultra-high energy density microbatteries San Jose, California, United States – Ensurge  (OSE: ENSU), a global leader in solid-state microbattery technology, and Corning Incorporated (NYSE: GLW), one of the world’s leading innovators in glass, ceramics, and materials science, today announced a set of agreements to jointly develop Ensurge’s ultra-high performance solid-state microbatteries. The agreements establish a framework for the two companies to integrate Corning’s Ribbon Ceramic materials and process technology with Ensurge’s proven solid-state microbattery architecture. Together, the two companies aim to deliver an ultra-high energy density product line extension to commercialize batteries that power high-volume consumer, medical, industrial, and defense...

Faraday Future Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” StrategyFaraday Future Founder and Global Co-CEO YT Jia (L) Congratulates Chris Nixon Cox (R) on Becoming a Global Strategic Advisor for Faraday Future.Faraday Future Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” StrategyFaraday Future Appoints Chris Nixon Cox (front row, second from right) as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” Strategy. Mr. Cox will strengthen global investor relations, government affairs, and industrial partnerships and will join the planned FFAI Global Strategic Advisory Council.Mr. Cox will strengthen global investor relations, government affairs, and industrial partnerships and will join...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor UpdateFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Appoints Chris Nixon Cox as Global Strategic Advisor to Accelerate Global Expansion of “EAI + Crypto” Strategy.The Company signed with three B2B partners and received non-refundable deposits and non-binding preorders from them totaling more than 200 units of the FX Super One, following the FX Super One Middle East Final Launch on Oct. 28. Global asset management giant Vanguard’s Q3 13G filing showed it held about 7.1 million FFAI shares, up 36 percent from the end of Q2.LOS ANGELES, Nov. 02, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility...

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy and safety — — Progress in global and China trials, including FRUSICA-2, SANOVO, surufatinib’s PDAC and fanregratinib’s IHCC studies, advances HUTCHMED’s late-stage pipeline — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 02, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announced key research and development (R&D) and business updates presented during its R&D Updates event held on October 31, 2025. The event highlighted HUTCHMED’s progress in advancing innovative cancer and immunology treatments, including the introduction...

Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that it will provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical Study of BB-301 being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Webcast details:Date: November 3, 2025Time: 8:00 am ESTTo register for the webcast, please click here. About Benitec Biopharma Inc.Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the...

Leanne Heywood was most recently a senior international copper marketing executive with Rio Tinto PERTH, Australia, Nov. 02, 2025 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX/TSX: FFM) (FireFly or the Company) is pleased to announce the appointment of highly regarded resources executive and company director Leanne Heywood as an Independent Non-Executive Director. Ms Heywood, who is a Fellow of accounting body CPA Australia, has significant experience as an international executive in the mining sector. Most recently, she held a senior international copper marketing role with Rio Tinto Limited and, prior to that, she was Chief Financial Officer of a copper mine in the Rio Tinto portfolio. Ms Heywood currently serves as a Non-Executive Director of Deterra Royalties Limited (ASX: DRR), Snowy Hydro Limited, Lotus Resources Limited (ASX:...

Underground core drilling at Tomingley is focused on defining extensions to resources as well as improving confidence of Inferred Resources at McLeans and the Western Monzodiorite domain at Roswell. Both McLeans and the Western Monzodiorite are immediately adjacent to existing underground infrastructure.    Underground drilling comprising of 9 diamond holes for a total of 3,247 metres was completed to improve the confidence of the Inferred Resource at McLeans. This drilling discovered a second andesite with significant gold mineralisation, located approximately 150m to the west of the current resource. Significant gold intercepts hosted by the western andesite include:MCLUG013Dincl   26 metres grading 4.36 g/t Au from 112 metres;3.3 metres grading 22.8 g/t Au from 112.7 metres.MCLUG012D   10.7 metres grading 2.09 g/t Au from 105...

REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s pre-license inspection of Alvotech’s Reykjavik manufacturing facility that concluded in July 2025, must be satisfactorily resolved before this BLA for AVT05 can be approved. The FDA did not identify any other deficiencies with the application. The facility remains FDA approved to manufacture...

REYKJAVIK, ICELAND (November 2, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA’s pre-license inspection of Alvotech’s Reykjavik manufacturing facility that concluded in July 2025, must be satisfactorily resolved before this BLA for AVT05 can be approved. The FDA did not identify any other deficiencies with the application. The facility remains FDA approved to manufacture and continues...

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and report the first clinical data from the CaMMouflage Phase 1 clinical trial evaluating CB-011, an allogeneic anti-BCMA CAR-T cell therapy, in patients with r/r multiple myeloma. The Company will also report its anticipated pivotal phase 3 trial design for vispa-cel and next steps for the continued clinical development of...